NPY2R and breast carcinoma: In breast cancer, NPY1R expression was confirmed in 85% of primary human breast carcinomas and 100% of lymph node metastases exhibiting a switch from NPY2R expression in normal breast tissue to NPY1R dominant expression during cancer progression (56).